Review:
21 Cfr Part 11 (fda Regulations)
overall review score: 4.2
⭐⭐⭐⭐⭐
score is between 0 and 5
21 CFR Part 11 is a regulation established by the U.S. Food and Drug Administration (FDA) that sets forth the criteria under which electronic records and electronic signatures are considered trustworthy, reliable, and equivalent to paper records. It aims to ensure data integrity, security, and confidentiality in electronic systems used in regulated environments such as pharmaceuticals, biotech, and healthcare industries.
Key Features
- Establishes requirements for electronic recordkeeping and signatures
- Ensures data integrity and security through audit trails, access controls, and system validations
- Defines criteria for digital signatures to be legally binding
- Specifies procedures for electronic record management and storage
- Aims to promote confidence in electronic regulatory submissions
Pros
- Enhances efficiency by allowing electronic documentation and workflows
- Provides clear guidelines for compliance and validation of electronic systems
- Strengthens data security with audit trails and access controls
- Facilitates modernization of record-keeping processes in regulated industries
Cons
- Can be complex to implement due to detailed technical requirements
- Requires significant resources for validation, training, and system updates
- Ambiguities in some provisions may lead to interpretation challenges
- Compliance efforts can be costly, especially for smaller organizations